Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

The only question is whether it's too late for new investors to cash in.

This Vaccine Stock Is a Money Machine in the Making

The vaccine appears to protect against the new variants.

Novavax's Vaccine Data Keeps Getting Better

iBio

Moderna

Ocugen, Inc.

VanEck Vectors Pharmaceutical ETF

Sorrento Therapeutics Inc

AstraZeneca

Pharmaceutical stocks gained a lot from the pandemic and the race to vaccines, but most of that upside is off the table now. The post 7 Pharmaceutical Stocks That Could Get a Covid Hangover appeared first on InvestorPlace.

7 Pharmaceutical Stocks That Could Get a Covid Hangover

President Biden is contemplating suspending intellectual property rights for COVID-19 vaccines.

Suspending Vaccine IP Rights Could Sink Moderna, Novavax

Could Novavax Be Too Late to the Party to Win in the U.S. COVID Vaccine Market?

It's all about potential products and revenue.

Here's Why The Best Is Yet to Come for Novavax

GlaxoSmithKline

GlaxoSmithKline PLC (LON:GSK) announced it will help making up to 60mln doses of the COVID-19 vaccine candidate (NVX-CoV2373) developed by Novavax, Inc. (NASDAQ:NVAX). The FTSE 100 firm signed an agreement in principle with Novavax and the UK Government.

GlaxoSmithKline to help making 60mln Novavax COVID-19 vaccine doses in UK plant

NVAX has a $13 billion market capitalism. This is driven by its potential sales of COVID-19 vaccines. NVAX is still awaiting regulatory approval. MRNA, PFE and JNJ are rapidly cutting supply deals. The lion's share of the estimated 2021 COVID-19 vaccine market is likely taken already.

Novavax Is 50% Overvalued

LONDON and GAITHERSBURG, Md., March 29, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax' COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK.

GSK to support manufacture of Novavax' COVID-19 vaccine

GlaxoSmithKline Plc (NYSE: GSK) has agreed to handle the final part of the manufacturing process for up to 60 million doses of Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine for use in the U.K. GSK will provide ‘fill and finish' manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May.

Glaxo To Fill About 60M Novavax COVID-19 Shots For Britain

The Serum Institute of India says the jointly developed Covovax has an overall efficacy of 89%.

Moderna vaccine to arrive in U.K. imminently as India starts testing Novavax inoculation

Moderna Vaccine Set to Arrive in U.K. as India Starts Testing Novavax Inoculation

The stock price of Novavax, Inc. (NASDAQ: NVAX) has received a price target decrease from $397 to $365. These are the details.

NVAX Stock Price: $365 Target (Down From $397) By B. Riley

Novavax is reportedly struggling to access the raw materials it needs to produce its Covid vaccine. But NVAX stock rebounded early Friday.

Novavax Stock Reverses Higher Despite Reports Of Covid Vaccine Delays

Baidu

Carnival

Darden Restaurants

Bitcoin, Carnival Cruise, Darden Restaurants, Novavax and Baidu were our top stock trades for Friday. Now, let's look at the charts.

5 Top Stock Trades for Friday: Bitcoin, CCL, DRI, NVAX, BIDU

Investors in NVAX stock appear concerned today over news a supply deal with the E.U. could be further away than previously thought.

NVAX Stock Alert: The Big Vaccine News That Has Novavax Plummeting

BioNTech SE

Johnson & Johnson

Pfizer

Viatris

This question has multiple right answers.

Which COVID Vaccine Stock Is the Best Pick?

Alpha Pro Tech

DocuSign

Peloton

Because of the pandemic, many so-called Covid stocks enjoyed outsized gains but investors might want to consider trimming their exposure. The post Take Your Profits!

Take Your Profits! 7 Covid Winners to Sell Now

iShares Nasdaq Biotechnology ETF

Vir Biotechnology

SPDR S&P Biotech ETF

Short-term investors may not see the long-term potential.

Here's Why Clinical-Stage Biotechs Get Hit Harder During a Market Decline

Some stocks could be big winners and losers depending on what the answer to this question is.

The Multibillion-Dollar Question: How Long Do COVID Vaccines Last?

GameStop

Penn Entertainment

Plug Power

With gains ranging from 1,100% to 4,900%, these big businesses have been unstoppable.

5 Large-Cap Stocks That Turned $100,000 Into $1 Million in 1 Year

Birks Group

Express

Koss

Marathon Digital Holdings

Cassava Sciences Inc

Sino-Global Shipping America

If nothing happens – and that's the hope – this article will be nothing but a good laugh. However, astute investors should at least know about these stocks that could crash.

7 High-Flying Stocks That Could Crash 20% or Even More

Novavax, Inc. (NASDAQ: NVAX) stock has pulled back sharply since hitting an all-time high of $331.68 on Feb 9. Will the weakness bring traders back into the stock?

Novavax Stock Down 32% From Recent Highs: Is The COVID-19 Play A Buy Ahead of Key Readouts?

News for Novavax Stock (NVAX)